Also known as: Eris Lifesciences, Eris Life Sciences
Eris Lifesciences is an India-based pharmaceutical company focused on branded formulations for chronic and sub-chronic therapies. Its portfolio covers areas including anti-diabetes, cardiovascular, dermatology, neuroscience, and oncology.
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Natco Pharma has received CDSCO approval to manufacture and market generic semaglutide injection in India, with a planned March 2026 launch. Eris Lifesciences will commercialize the product through a partnership.
The patent for semaglutide, the active ingredient in Ozempic, expires March 20, 2026. Indian pharmaceutical companies are preparing to launch generic versions, with prices expected to be 30-50% lower than branded products.
NATCO Pharma has licensed its semaglutide generic formulation to Eris Lifesciences for the Indian market, with a launch expected in March 2026 following CDSCO approval. The partnership targets type 2 diabetes management as the molecule loses patent exclusivity in India.
Swiss pharmaceutical major Novartis AG has signed a definitive agreement to sell its entire 70.68% stake in Novartis India to a ChrysCapital-led consortium for Rs 1,446 crore, with a mandatory open offer for an additional 26% from public shareholders.
